Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Year Ahead: Controversial NDAs Could Entangle FDA In ‘08; Where Are The Oncologics?

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Looking ahead at FDA’s review calendar for 2008, the agency will be wrestling with several enigmatic decisions as it considers applications for fibromyalgia and chronic fatigue syndrome, controversial diseases with nebulous definitions and diagnoses.

You may also be interested in...



Savella's Secret? "Unknown Factor" Could Be Key To Symptom Relief

The effect of Forest’s fibromyalgia therapy Savella (milnacipran) on a composite responder endpoint in Phase III did not correspond to the results for individual components of that endpoint, an "unusual finding" that the reviewing FDA division director suggested could result from the drug’s effect on an "unknown factor."

Hemispherx Ampligen Amendment Will Jumpstart NDA Clock

Biopharma prepares to respond to all 14 deficiencies cited in FDA’s refuse-to-file letter for the Toll-like receptor-3 agonist. Firm also exploring drug’s use as an adjuvant for HIV/AIDS and avian influenza vaccines

Hemispherx Ampligen Amendment Will Jumpstart NDA Clock

Biopharma prepares to respond to all 14 deficiencies cited in FDA’s refuse-to-file letter for the Toll-like receptor-3 agonist. Firm also exploring drug’s use as an adjuvant for HIV/AIDS and avian influenza vaccines

Related Content

Topics

UsernamePublicRestriction

Register

PS003778

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel